Have your say!
Would you like to share your views to help improve programs and services for patients, or help researchers gain a better understanding of the challenges of living with kidney disease?
Our Kidney Community Contact List is a national and confidential record of people willing to be contacted for their feedback and action on topics of concern to people living with kidney disease. Join our contact list and we will contact you as opportunities arise.
Seeking Patients and Nurses Feedback on AK96 and AK95 Home Dialysis Machines
CRC Research is seeking patients and nurses using AK96 and AK95 home dialysis machines to participate in a 2.5 hour interview in Mississauga, Ontario between Nov. 24 to Dec. 3, 2014. Participants will be remunerated and those travelling to the interview within a two-hour radius will have their mileage reimbursed.
To confirm your eligibility please fill out this online questionnaire: https://www.surveymonkey.com/s/8NVLGKZ
Eligible participants should contact Aziza Oubella at 1-866-272-4959 or by email at email@example.com.
Walking and Health in Adults with a Kidney Transplant
Researchers at Athabasca University want to learn about the health outcomes associated with walking behaviour in adult kidney transplant recipients.
Study participants must be over the age of 18, have a functioning kidney transplant, be able to walk without assistance (cane, walker, wheelchair), and be able to read and understand English. Participants will be asked to wear a pedometer for three days and record their number of steps, then complete and return a survey (postage paid).
Download this document for more information or contact Ms. Josée Raymond at 249-878-0088 or via email at firstname.lastname@example.org.
Clinical Trial Studying New Non-surgical Vascular Access Method for Hemodialysis
The Novel Endovascular Access Trial (NEAT) is evaluating the safety and efficacy of the FLEX endoAVF System from TVA Medical, a device that creates an arteriovenous fistula (AVF) in a percutaneous procedure, without general anesthesia or surgery. In the procedure, two thin, flexible magnetic catheters are inserted in an artery and vein in the arm. A small burst of radiofrequency energy is used to connect the artery and vein to create the fistula, and the catheters are removed. The procedure is designed to enable patients to use their AVF for hemodialysis within one to two months.
Five hospitals in Canada are enrolling up to 70 patients in total who will be followed for 12 months in the NEAT clinical trial. The centers include St. Paul’s Hospital in Vancouver; Montreal University Health Centre (CHUM) in Montreal; Toronto General Hospital in Toronto; Lakeridge Health in Oshawa, Ontario; and Victoria Hospital in London, Ontario. NEAT study participants must be willing to travel to one of the trial sites on a monthly basis for one year for hemodialysis and follow-up appointments.
Patients with end-stage (stage IV or V) renal disease interested to enroll in this trial should read this Patient FAQ and talk to their nephrologist before contacting the participating hospital in their region.
Determining the Research Priorities of Canadian Kidney Cancer Patients, Caregivers and Clinicians: A Priority Setting Partnership for Kidney Cancer
Patients, caregivers and healthcare professionals should have a voice in determining the research priorities of this disease. But, healthcare research often neglects these voices. This project brings together this group to collaboratively establish the top 10 research priorities for the diagnosis and management of kidney cancer.
The survey takes approximately 10 to 20 minutes to complete. We ask you to list any questions you have about diagnosis, prognosis, treatment, and anything else that you think should be studied through research. The survey will be open until November 30, 2014.
This study is being conducted by the Kidney Cancer Research Network of Canada in a partnership with the James Lind Alliance (JLA) and with support from the Canadian Institute of Health Research (CIHR), Kidney Cancer Canada (KCC) and the Kidney Foundation of Canada (KFofC).